MY112413A - Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals - Google Patents

Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals

Info

Publication number
MY112413A
MY112413A MYPI94002894A MYPI19942894A MY112413A MY 112413 A MY112413 A MY 112413A MY PI94002894 A MYPI94002894 A MY PI94002894A MY PI19942894 A MYPI19942894 A MY PI19942894A MY 112413 A MY112413 A MY 112413A
Authority
MY
Malaysia
Prior art keywords
pharmaceuticals
preparation
substituted heterocyclic
heterocyclic carboxamides
carboxamides
Prior art date
Application number
MYPI94002894A
Inventor
Klaus Weidmann Dr
Karl-Heinz Baringhaus Dr
Georg Tschank Dr
Martin Bickel Dr
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4337271A external-priority patent/DE4337271A1/en
Priority claimed from DE19944410881 external-priority patent/DE4410881A1/en
Priority claimed from DE19944433928 external-priority patent/DE4433928A1/en
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MY112413A publication Critical patent/MY112413A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

THE INVENTION RELATES TO COMPOUNDS OF THE FORMULA I,FORMULATO A PROCESS FOR THEIR PREPARATION AND TO THEIR USE AS PHARMACEUTICALS. THE COMPOUNDS ARE EMPLOYED, IN PARTICULAR, FOR INHIBITING COLLAGEN BIOSYNTHESIS AND AS INHIBITORS OF PROLYL HYDROXYLASE AND AS FIBROSUPPRESSIVEAGENTS.
MYPI94002894A 1993-11-02 1994-10-31 Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals MY112413A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4337271A DE4337271A1 (en) 1993-11-02 1993-11-02 ubstd. heterocyclic carboxylic acid amides and their prepn.
DE19944410881 DE4410881A1 (en) 1994-03-29 1994-03-29 Substd. heterocyclic carboxylic acid amides and their prepn.
DE19944433928 DE4433928A1 (en) 1994-09-23 1994-09-23 Substd. heterocyclic carboxylic acid amides and their prepn.

Publications (1)

Publication Number Publication Date
MY112413A true MY112413A (en) 2001-06-30

Family

ID=27205714

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI94002894A MY112413A (en) 1993-11-02 1994-10-31 Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals

Country Status (19)

Country Link
EP (1) EP0650961B1 (en)
JP (1) JPH07228571A (en)
KR (1) KR950014072A (en)
CN (1) CN1107145A (en)
AT (1) ATE149486T1 (en)
AU (1) AU676775B2 (en)
CA (1) CA2134866A1 (en)
CY (1) CY2120B1 (en)
CZ (1) CZ289356B6 (en)
DE (1) DE59401924D1 (en)
DK (1) DK0650961T3 (en)
ES (1) ES2101421T3 (en)
GR (1) GR3023174T3 (en)
IL (1) IL111454A (en)
MY (1) MY112413A (en)
NO (1) NO301880B1 (en)
NZ (1) NZ264821A (en)
PL (1) PL179794B1 (en)
TW (1) TW399046B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
DE19746287A1 (en) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
FR2803592A1 (en) * 2000-01-06 2001-07-13 Aventis Cropscience Sa NOVEL DERIVATIVES OF 3-HYDROXYPICOLINIC ACID, PROCESS FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME
DE10123587B4 (en) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamide derivatives and their use as pharmaceuticals
DE10123573B4 (en) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamide derivatives and their use as pharmaceuticals
DE50206476D1 (en) 2001-05-08 2006-05-24 Schering Ag CYANOANTHRANYLAMID DERIVATIVES AND THEIR USE AS DRUGS
CN102526045A (en) 2001-12-06 2012-07-04 法布罗根股份有限公司 Methods of increasing endogenous erythropoietin EPO
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
CN101664553B (en) * 2001-12-06 2013-08-21 法布罗根股份有限公司 Stabilization of hypoxia inducible factor (HIF) alpha
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
KR100932169B1 (en) 2003-06-06 2009-12-16 피브로겐, 인크. Nitrogen-containing heteroaryl compounds and their use in the increase of endogenous erythropoiesis
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
CN101166745A (en) 2005-03-02 2008-04-23 菲布罗根有限公司 Novel thienopyridine compounds, and methods of use thereof
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
ATE470439T1 (en) 2005-06-15 2010-06-15 Fibrogen Inc USE OF HIF 1ALFA MODULATORS TO TREAT CANCER
WO2007090068A2 (en) 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
EP2016078B1 (en) * 2006-04-04 2016-06-15 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
WO2009002533A1 (en) 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
ES2360929T3 (en) * 2007-09-20 2011-06-10 Amgen Inc. ACID DERIVATIVES 1- (4- (4-BENCILBENZAMIDO) -BENCIL) AZETIDIN-3-CARBOXYL AND RELATED COMPOUNDS AS MODULATORS OF THE S1P RECEPTOR FOR THE TREATMENT OF IMMUNE DISORDERS.
CN102272117B (en) 2008-11-14 2015-06-17 菲布罗根有限公司 Benzothiopyran derivatives as HIF hydroxylase inhibitors
KR101007674B1 (en) * 2010-08-13 2011-01-13 김병두 High speed spray gun and coating device with auxiliary cap
KR101007675B1 (en) * 2010-08-13 2011-01-13 김병두 Plasma spray gun with auxiliary cap and plasma spray system using the same
NO2686520T3 (en) 2011-06-06 2018-03-17
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
KR101629767B1 (en) 2012-07-04 2016-06-13 아구로카네쇼 가부시키가이샤 2-Aminonicotinic acid ester derivative and bactericide containing same as active ingredient
US9340511B2 (en) 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9115085B2 (en) 2012-07-16 2015-08-25 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
WO2014116849A1 (en) 2013-01-24 2014-07-31 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of a hif hydroxylase inhibitor
SMT202400092T1 (en) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Compositions and methods for treating anemia
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
HK1247201A1 (en) 2015-01-23 2018-09-21 阿克比治疗有限公司 Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (en) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3- hydroxypyridine compound, preparation method and its pharmaceutical applications
PL3277270T3 (en) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF ISKNIA
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
PL3808747T3 (en) * 2018-09-13 2025-03-17 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (en) 1990-05-12 1991-11-14 Hoechst Ag OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE
EP0541042A1 (en) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft 2,4- and 2,5-pyridine-dicarboxylic acid derivatives, process for their preparation and their use
JPH07504654A (en) * 1992-03-11 1995-05-25 ナルヘックス リミテッド Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
PL305646A1 (en) 1995-05-15
IL111454A0 (en) 1994-12-29
AU7756494A (en) 1995-05-18
CA2134866A1 (en) 1995-05-03
KR950014072A (en) 1995-06-15
CZ289356B6 (en) 2002-01-16
HK1006711A1 (en) 1999-03-12
ES2101421T3 (en) 1997-07-01
CZ268394A3 (en) 1995-05-17
IL111454A (en) 2001-08-08
NZ264821A (en) 1997-02-24
EP0650961B1 (en) 1997-03-05
NO301880B1 (en) 1997-12-22
PL179794B1 (en) 2000-10-31
NO944162L (en) 1995-05-03
TW399046B (en) 2000-07-21
AU676775B2 (en) 1997-03-20
NO944162D0 (en) 1994-11-01
CN1107145A (en) 1995-08-23
JPH07228571A (en) 1995-08-29
CY2120B1 (en) 2002-04-26
ATE149486T1 (en) 1997-03-15
DE59401924D1 (en) 1997-04-10
GR3023174T3 (en) 1997-07-30
EP0650961A1 (en) 1995-05-03
DK0650961T3 (en) 1997-09-15

Similar Documents

Publication Publication Date Title
IL111454A0 (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
MY131657A (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
PH31264A (en) Substituted heterocyclic carboxamide esters, and their use as pharmaceuticals.
GEP20033028B (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
CA2107105A1 (en) Heterocyclic-cyclic amine derivatives
AU5488498A (en) Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
PL327275A1 (en) Matalproteinase inhibitors, pharmaceutic compositions containing them and their application as well as method of and substrates for obtaining them
AU2364600A (en) Heteroroaromatic amides as inhibitor of factor xa
AU4712396A (en) Chiral methylphenyloxazolidinones
AU5875498A (en) Substituted derivatives of benzosulphonamides as inhibitors of the enzyme cyclo oxygenase ii
MX9800408A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts.
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
NO984740L (en) Isatin derivatives such as acetylcholinesterase inhibitors and analgesics
ES8707538A1 (en) 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments.
WO2002014313A3 (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments
CA2218663A1 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
HUP0202988A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0103020A3 (en) Heterocyclic derivatives as fkbp inhibitors, process for their preparation, their intermediates and pharmaceutical compositions containing them
DE69801811D1 (en) ALKYKENDIAMIN DI- OR TRI-ACETIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN COSMETIC COMPOSITIONS
MY112414A (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
AU650511B2 (en) 2,4- and 2,5-bistetrazolypyridines, a process for the preparation thereof and the use thereof as pharmaceuticals
ATE228359T1 (en) INHIBITION OF LEUKOTRIE BIOSYNTHESIS USING UREA DERIVATIVES
MX9710530A (en) BENZO[g]QUINOLINE DERIVATIVES.